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The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin’s lym-
phoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing
regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an impor-
tant contributor to both the health status and the selection of treatment, cardiovascular profiling and
baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment
is an efficient means of identifying elderly patients with non-Hodgkin’s lymphoma who may benefit from
a curative treatment approach. If anthracycline-based therapy is not suitable, alternative treatment op-
tions are available in frail patients with cardiac comorbidities, but these must be adjusted to the patient’s
health status to achieve a maximal benefit–risk ratio.
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Diffuse large B-cell lymphoma is a potentially curable disease with currently available therapies. However, the
treatments with the most potential for cure – the anthracycline-based chemotherapy regimens – are often a limited
treatment option for the elderly, for the frail or for those with cardiac comorbidities. This is due to a higher
susceptibility to treatment toxicity, a different physiology for elderly subjects and the role of comorbid conditions.
Although there is a known disconnect between chronological age and the health status of a patient, there is currently
a lack of assessment tools for physicians to accurately assess patient frailty.
Here we discuss the evaluation of frailty in older patients with aggressive non-Hodgkin’s lymphoma (NHL) and
we provide guidance on how to select treatment options depending on the health status of a patient. As cardiac
comorbidities are an important contributor to both the health status and the selection of treatment, we especially
focus on the diagnosis and monitoring of cardiac status in elderly patients with NHL.
Frail patients: what do we need to know?
NHL is one of the most common types of cancer, comprising 4.3% of total cancers. Reports estimate 70,000 new
cases and 20,000 deaths in the USA in 2017 [1,2]. Notably, NHL is most frequent in people aged 65–74 years [3],
and as the population ages, NHL is expected to become more prevalent. Diffuse large B-cell lymphoma (DLBCL)
is the most common form of NHL (31% of cases) [4] and is curable in a large percentage of patients. The most
widely accepted form of first-line therapy is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone) [5].
Real-world data from the Netherlands show that trends in 5-year survival have improved over the last two
decades. The prognosis for DLBCL has improved for all age groups, but less so for those over 75 years of age [6].
Consideration of the inferior outcome in the elderly is warranted; elderly patients may well be undertreated because
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prescribers are fearful of chemotherapy-induced toxicities. Alternatively, elderly patients are under-represented in
clinical trials because they are usually not included due to multiple comorbidities or poor performance status. In
their study, Van Spronsen et al. found that 66% of patients with NHL older than 60 years of age have one or more
comorbidities [7]. Among these patients, cardiovascular disease is common, and has a strong prognostic influence.
Overall 5-year survival in NHL patients (aged >60 years) was significantly less in those with two or more than in
those with no comorbidities (hazard ratio: 1.9) [7]. Moreover, the more comorbidities a patient had, the less likely
he or she was to receive curative therapy [7].
The primary reason for a poor outcome in elderly patients is their decreased ability to tolerate treatment [8].
Impaired bone-marrow function, altered drug metabolism and the presence of comorbid diseases can increase the
number of treatment-related complications [9]. However, it is possible to improve outcomes for the elderly patient
with NHL [9]. In a study of 150 elderly patients (median age: 83 years), treated with an R-mini-CHOP regimen,
2-year overall survival (OS) was 59% (49–67%), median progression-free survival was 21 months (95% CI: 13 to
upper limit not reached) and 2-year progression-free survival was 47% (38–56%). However, it should be noted
that patients with severe comorbidities (especially cardiac comorbidities) were excluded from this study [9]. The
decisive factor in selecting a treatment regimen for an elderly patient with aggressive NHL is to ascertain whether
a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or is too frail and therefore at
risk of being undertreated. Definitions of frailty are changing and evolving but currently there is no consensus.
Frailty is an important concept in cancer therapy because it is estimated that greater than half of older cancer
patients have prefrailty or frailty, and these patients are at increased risk of chemotherapy intolerance, postoperative
complications and mortality [10].
Identifying & monitoring cardiac comorbidity
Considering that there is an increase in the number of long-surviving cancer patients who present with cardiovascular
disease, there is growing importance for a multidisciplinary team approach with the inclusion of a cardiologist as part
of a cancer patient’s management team, and the development of new cardio-oncology specialists to meet this clinical
need. This approach aims to prevent the hematology patient of today becoming the cardiac patient of tomorrow.
The diametrically opposed relationship between cancer (cell division, increased cell number, angiogenesis, increased
metabolic disease, drug/toxin resistance) and heart disease (failure of cell division/tissue repair, cell loss, ischemia,
impaired/decreased energetic efficiency, increased sensitivity to toxins), that is, the cardio-oncology balance, provides
healthcare providers with an opportunity to prevent, rather than respond to, therapeutic cardiotoxicity.
R-CHOP remains the standard regimen in patients with aggressive NHL. However, the utility of doxorubicin is
limited by cumulative, dose-related, progressive myocardial damage that can lead to congestive heart failure (CHF).
Age is an important risk factor for doxorubicin-related CHF, with patients over 65 years of age experiencing a higher
incidence of CHF when compared with patients younger than 65 years [11]. Retrospective analysis estimates the
5-year incidence of cardiac events in NHL patients treated with CHOP/R-CHOP to be approximately 29% [12].
Anthracycline-based chemotherapy, which improves survival in aggressive NHL, is often withheld from elderly
patients because of potentially cardiotoxic effects. In an American study that enrolled 9438 patients with DLBCL
aged ≥65 years, only 42% of patients received doxorubicin-based chemotherapy. Doxorubicin use was associated
with a 29% increase in CHF (95% CI: 1.02–1.62), with absolute risk influenced by age, the number of doxorubicin
cycles and the presence of pre-existing cardiovascular disease [13]. Real-world, prospective data from an Italian cohort
(n = 2625 patients receiving anthracycline-based chemotherapy) showed that the overall incidence of cardiotoxicity
was 9% (n = 226), the median time elapsed between end of chemotherapy treatment and the development of
clinical cardiotoxicity was 3.5 months (Q1–Q3: 3–6) and that, in 98% of cases (n = 221), cardiotoxicity occurred
within the first year [14]. It should be noted that the patients included in this real-world cohort were aged >18
years, that is, they were not an elderly population [14]. Such findings support a management strategy of assessing a
patient’s cardiac function within 3–4 months of initiating anthracycline-based chemotherapy.
The cardiac pathophysiology of anthracyclines is believed to involve the generation of reactive oxygen species,
which results in damage to DNA, proteins and lipids, and leads to cellular dysfunction and cardiomyocyte death [15].
However, an alternative hypothesis suggests that the first step in anthracycline-mediated cardiomyocyte damage is
independent of reactive oxygen species and depends instead on drug interactions with a type of topoisomerase, an
enzyme that affects the tension and topologic features of DNA [16]. The elucidation of the underlying molecular
mechanism(s) involved in anthracycline-induced injury to cardiac cells has resulted in the development of numerous
novel, targeted therapies and an increasingly complex therapeutic milieu.
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Box 1. Baseline cardiovascular risk factors.
Previous cardiovascular disease
• Heart failure
• Ischemic heart disease
• Borderline left ventricular ejection fraction
• Left ventricular hypertrophy
• Elevated cardiac biomarkers
Demographic and other cardiovascular risk factors
• Age >65 years
• Female gender
• Hypertension
• Diabetes
• Renal failure
Previous cardiotoxic cancer treatment
• Anthracyclines
• Chest radiation with heart within radiation field
• VEGF TKIs
Lifestyle risk factors
• Obesity
• Smoking
TKI: Tyrosine kinase inhibitor.
Cardiologists advocate methods that can ameliorate the cardiotoxicity of doxorubicin; the most important is
cardiovascular profiling and baseline risk stratification prior to treatment (Box 1) [19,21]. Other options include close
surveillance of the cardiac status of patients with cardiac biomarkers/imaging during treatment, use of liposomal
doxorubicin, dexrazoxane or the use of an alternative nonanthracycline-based chemotherapy [17–19]. There is
no evidence that prolonged infusion ofanthracycline is more beneficial over bolus in terms of cardiotoxicity.
Modern echocardiography techniques, such as speckle tracking echocardiography, permit early detection of cardiac
dysfunction. Speckle tracking can be used to measure loss of cardiac global longitudinal strain, known to precede a
reduction in ejection fraction and may be a useful predictor of when intervention is required to manage potential
cardiotoxicity. Cardiac injury biomarker assessment is another useful tool during chemotherapy. Measurement of
troponin I, after high cumulative dose (300 mg) anthracycline chemotherapy, permits stratification of the risk of
cardiac events in cancer patients in the 3 years thereafter [20].
Cardio-oncology services play a vital role in supporting patients experiencing cardiotoxicity during cancer treat-
ment in order to complete their treatment safely [22]. The key to success is a multidisciplinary team approach
across hematology, oncology and cardiology, all members of which work to minimize the delay to cancer treat-
ment and support, not obstruct, cardiotoxic cancer treatments. Best practice includes rapid assessment without
introducing delays, cardiac biomarker measurement (troponin, brain natriuretic peptide), resting echocardiography
with speckle and 3D imaging, with stress echocardiography ± contrast perfusion, cardiac MRI and computed
tomography coronary angiography in selected patients, and same day results/treatment plan.
Assessing the elderly or frail patient
Clearly there is a need for individualized care in the elderly cancer patient. Yet, the definition for ‘elderly’ or ‘frail’
is not clear. Learned bodies, including the International Society of Geriatric Oncology, the European Organisation
for Research and Treatment of Cancer, and the European Society for Medical Oncology (ESMO) suggest the term
‘elderly’ or ‘old’ should be used for all patients aged >70 years, yet, chronological age alone is a poor predictor
of cancer treatment tolerance [23] and the heterogeneity of the older cancer patient requires a carefully tailored
approach to care that considers individual frailty [10]. Due to the disconnect between numerical age and health
status, prescribers face a dilemma when deciding who is suitable for treatment with a doxorubicin-containing
regimen, and if suitable, which dose and therapeutic goals should be prescribed.
OS is but one of several treatment objectives in the elderly and/or frail patient with DLBCL. Consideration
of the overall complexity of the patient is warranted, including tolerability, toxicity, comorbidities, potential for
early death, quality of life, functional decline and, most importantly, the wishes of the patient [24–26]. Social
status impacts on patient outcomes and geriatric assessment should also pay attention to the availability of family
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Table 1. European Society for Medical Oncology treatment guidelines for diffuse large B-cell lymphoma.
Fit, 60–80 years >80 years without cardiac dysfunction Unfit or frail or >60 years with cardiac dysfunction
R-CHOP Attenuated regimens: R-mini-CHOP Doxorubicin substitution
– Etoposide
– Gemcitabine
– Liposomal doxorubicin
– Others
R-CVP
R-bendamustine
Palliative care
R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP: Rituximab, cyclophosphamide, vincristine, prednisolone.
support, the living situation, social activity and caregiver burden [27]. Several well-validated tools are available for
measuring comorbidities, such as, the Cumulative Illness Rating Scale (CIRS) and the Charlson Comorbidity Index
(CCI) [28,29]. Recent data from Pardal et al. demonstrate that, simple prognostic models, like the CIRS, may aid in
the selection of DLBCL patients who could benefit from a curative treatment [30].
According to International Society of Geriatric Oncology, a comprehensive geriatric assessment (CGA), with or
without screening, and with follow-up, should be used in older cancer patients, to detect unaddressed problems,
improve their functional status and possibly their survival [31]. Despite this recommendation, and the utility of
the CGA, there are some disadvantages associated with this assessment. The CGA is relatively complex, time-
consuming and must be administered by a geriatrician. Simplified screening tools are needed and could include
the G-8 geriatric screening tool [32], the Vulnerable Elders Survey (VES-13) [33] or the simplified CGA [34]. In
2015, Tucci et al. reported that the simplified CGA can identify elderly, nonfit patients with DLBCL, in whom
curative treatment has no advantage over palliative care. Patients (n = 173) aged >69 years, treated with curative or
palliative intent, were grouped according to CGA into fit, unfit and frail categories. The results showed that 2-year
OS was significantly better in fit than in unfit patients (84 vs 47%; p < 0.0001) and that survival in unfit and frail
patients was not significantly different. Curative treatment slightly improved 2-year OS in unfit (75 vs 45%) but
not in frail patients (44 vs 39%). The authors suggest simplified CGA is an efficient means of identifying elderly
patients with DLBCL who may benefit from a curative treatment approach [35].
Therapy options for frail patients with DLBCL
The complex pathophysiology of elderly patients with malignant lymphoma presents a clinical challenge. Less
aggressive treatment may reduce the chances of cure, prolongation of life and/or symptom control, whereas an
aggressive treatment may result in treatment-related morbidity and mortality, and/or compromised quality of life.
Thus, a cornerstone in the decision-making process is to judge fitness for treatment [36]. The ESMO guidelines
propose that ‘fitness’ is defined in the context of treatment feasibility with three different categories discriminating
between ‘fit’, ‘vulnerable’ and ‘terminally ill’ patients. For an elderly ‘fit’ patient, it would be anticipated that
application of the standard treatment, including more dose-intense approaches, would not be associated with a
high risk of treatment-related or treatment-unrelated adverse events (AEs) compared with a young ‘fit’ patient.
In contrast a ‘vulnerable’ patient would carry a high risk for treatment-related AEs or treatment-unrelated AEs
when receiving standard treatment. Vulnerable patients would present a continuum, ranging from those who are
just at the border of not being able to tolerate standard treatment to those who are close to being considered
as terminally ill [36]. ESMO recommends that fit patients, aged 60–80 years, are offered curative therapy with
R-CHOP (Table 1) [36,37]. The very elderly (aged >80 years), without cardiac dysfunction, should be treated with
an attenuated anthracycline-containing regimen (R-mini-CHOP) and the elderly/frail, with cardiac dysfunction,
are generally treated with an alternative or palliative therapy [36,37].
Liposomal doxorubicin combination therapy or the replacement of doxorubicin with etoposide is an option in
elderly and cardiac frail patients. Evidence suggests that many patients (44–78%) experience a complete response,
but, at the expense of a decline in left ventricular ejection fraction [38–42]. One may also consider anthracycline-free
combination therapy in elderly and cardiac frail patients, though this is known to result in an attenuation of the
complete response [43].
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Is the patient eligible for ASCT second line?
Aim for a cure
Yes
No
Palliation with optimization of risk/benefit ratio of
treatment, consider:
      –      Available non-cross resistant agents
      –      Residual toxicity from first-line therapy
      –      Individualization of treatment – assess
             activity and toxicity profiles of drugs
Figure 1. Proposed decisional algorithm in relapsed/refractory elderly, frail diffuse large B-cell lymphoma patients.
ASCT: Autologous stem cell transplantation.
Box 2. Potential treatment regimens for elderly patients with relapsed/refractory diffuse large B-cell
lymphoma not eligible for autologous stem cell transplantation.
• PECC: Prednisone, etoposide, chlorambucil, lomustine, ± R
• CEPP: Cyclophosphamide, etoposide, prednisone, procarbazine, ± R
• CEOP: Cyclophosphamide, etoposide, vincristine, prednisone, ± R
• GDP: Gemcitabine, dexamethasone, carboplatin, ± R
• GemOX: Gemcitabine, oxaliplatin, ± R
• Lenalidomide ± R
• Bendamustine ± R
• Palliative RT
R: Rituximab; RT: Radiation therapy.
Therapy options in patients with relapsed DLBCL after anthracycline-containing first-line therapy
In the relapsed setting, cardiac toxicity is more difficult to manage compared with first-line therapy, as patients have
often already received anthracycline first line or were treated with a doxorubicin-free regimen due to pre-existing
cardiac problems. Figure 1 shows a suggested decisional algorithm in relapsed/refractory frail DLBCL patients. In
addition, Box 2 lists some potential therapeutic strategies in elderly patients with relapsed/refractory DLBCL who
are not eligible for high-dose chemotherapy followed by autologous stem cell transplantation [45]. Few randomized
data are available from the literature to provide scientific support in the choice of a salvage therapy. Among available
studies the use of pixantrone is supported by Phase III data. Data from a global Phase III study, in patients with
aggressive NHL, who had relapsed after two or more previous chemotherapy regimens (including one standard
anthracycline-containing protocol) demonstrated median progression-free survival of 5.2 months (95% CI: 2.3,
6.2) in patients treated with pixantrone monotherapy versus 2.6 months (95% CI: 1.9, 3.5) in the comparator
group [44]. The most common grade 3 or 4 adverse events in patients given pixantrone were uncomplicated,
noncumulative neutropenia, leukopenia and thrombocytopenia; the severity of neutropenia did not increase with
increasing cycle number. Notably, the cardiac events that were reported were predominantly asymptomatic grade 1
and 2 reductions in left ventricular ejection fraction, which did not increase with increasing pixantrone exposure.
These results support the use of pixantrone as a treatment option for patients whose aggressive NHL has failed to
respond to at least two previous chemotherapy regimens [44].
Rituximab, cyclophosphamide, pixantrone, vincristine, prednisone
Pixantrone was synthesized with the aim of reducing anthracycline-related cardiotoxicity, without compromising
antitumor efficacy. In a Phase II study in which doxorubicin was substituted by pixantrone in untreated DLBCL
patients, R-CPOP (rituximab, cyclophosphamide, pixantrone, vincristine, prednisone) demonstrated a modestly
lower response rate than R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) but similar
progression-free and event-free survivals and a lower incidence of severe cardiac events [46]. These data do not support
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the use of R-CPOP as first-line therapy but demonstrate a substantial difference in the cardiotoxicity of pixantrone
compared with doxorubicin when used as first-line therapy [46].
Conclusion
The incidence of cardiotoxicity is increasing among patients undergoing anthracycline-based chemotherapy, partic-
ularly in the frail population where a careful assessment of the benefit–risk ratio is mandatory. Performing a baseline
cardiovascular assessment prior to the instigation of treatment is a vital part of cardio-oncology patient-centered
care. Easy-to-use, validated tools for assessing elderly patients are available, and can guide treatment goals and
options. Once the patient status has been determined, alternative treatment options are available in frail patients
with cardiac comorbidities, but these must be adjusted to the patient’s health status to achieve a maximal benefit–
risk ratio. In conclusion, frail patients represent an unmet need in lymphoma, and well-designed clinical trials are
warranted.
Future perspective
The treatment of elderly patients with aggressive NHL is often complicated due to comorbidities and they are often
on many drugs with potential interactions. In the future, our hope is that frail patients will receive tailored treatment,
which is equivalent to that prescribed to younger patients but which takes into consideration the socioeconomic
issues and wishes of the elderly patient. Key factors in achieving this goal will be a universally accepted definition
of frailty, routine geriatric and baseline cardiovascular risk assessment, and the development of new drug entities
with minimal or no cardiotoxicity, that can be administered at doses that do not compromise antitumor efficacy.
The literature is awash with studies looking at different frailty scaling and rating systems, which aim to assess
the fitness of older patients, particularly their ability to tolerate cancer treatments. None of these rating scales are
perfect, and all have their champions and detractors. In the future, we predict that, a simple, reliable geriatric
assessment tool will be available to enable professionals to treat and manage older people, and this assessment will
be used to guide therapeutic choices.
Treatment decisions are often based on clinical judgement, which varies between clinicians and may also be
subject to bias. Our ambition is that, by 2030, patients will be managed by multidisciplinary geriatric oncology
services, including geriatricians, hematologists, oncologists and cardiologists, all of whom will be working to
minimize the delay to treatment and to support, not obstruct, cancer treatments.
As things stand, we believe that our healthcare systems are not adequately prepared to meet the challenges of an
aging population with cancer. Clearly, more research is needed to address the specific needs of the elderly. A range
of national policies and practices is being introduced to help address this gap, but more must be done to ensure
that cancer services are equipped to meet the demands of the future, fronted by a global cancer care strategy for the
frail patient.
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Executive summary
Frail patients: what do we need to know?
• There is a known disconnect between chronological age and the health status of a patient.
• The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin’s lymphoma
is to ascertain whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or
too frail and therefore at risk of being undertreated.
Identifying & monitoring cardiac comorbidity
• The utility of doxorubicin is limited by cumulative, dose-related, progressive myocardial damage that can lead to
congestive heart failure.
• Cardiologists advocate methods that can ameliorate the cardiotoxicity of doxorubicin; the most important is
cardiovascular profiling and baseline risk stratification prior to treatment.
• Cardio-oncology services play a vital role in supporting patients experiencing cardiotoxicity during cancer
treatment to complete their treatment safely.
Assessing the elderly or frail patient
• Consideration of the overall complexity of the patient is warranted, including tolerability, toxicity, comorbidities,
potential for early death, quality of life, functional decline, social situation and most importantly, the wishes of
the patient.
• Comprehensive geriatric assessment, with or without screening, and with follow-up, should be used in older
cancer patients, to detect unaddressed problems, improve their functional status and possibly their survival.
Treatment options for frail patients
• Alternative treatment options are available in frail patients with cardiac comorbidities, but these must be
adjusted to the patient’s health status to achieve a maximal benefit–risk ratio.
• The European Society for Medical Oncology (ESMO) recommends that fit patients, aged 60–80 years, are offered
curative therapy with R-CHOP; very elderly patients (aged >80 years), without cardiac dysfunction, should be
treated with an attenuated anthracycline-containing regimen (R-mini-CHOP); and the elderly/frail, with cardiac
dysfunction should be treated with an alternative or palliative therapy.
• In the relapsed setting, cardiac toxicity is more difficult to manage than in first-line therapy, as patients have
often already received anthracycline first line or were treated with a doxorubicin-free regimen due to
pre-existing cardiac problems.
• Few randomized studies are available from the literature to provide scientific support in the choice of a salvage
therapy. Among available studies the use of pixantrone in the multiply relapsed/refractory setting is supported
by Phase III data.
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